Liposomal amphotericin B can safely be administered in paediatric outpatients with cancer for the primary or secondary prevention of invasive aspergillosis

Acta Haematol. 2007;118(2):68-9. doi: 10.1159/000102605. Epub 2007 May 29.
No abstract available

Publication types

  • Comment
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Amphotericin B / administration & dosage
  • Amphotericin B / therapeutic use*
  • Antifungal Agents / administration & dosage
  • Antifungal Agents / therapeutic use*
  • Aspergillosis / drug therapy
  • Aspergillosis / prevention & control*
  • Child
  • Child, Preschool
  • Female
  • Home Care Services, Hospital-Based*
  • Humans
  • Infant
  • Infusions, Intravenous / nursing
  • Liposomes
  • Male
  • Neoplasms / complications
  • Outpatients

Substances

  • Antifungal Agents
  • Liposomes
  • liposomal amphotericin B
  • Amphotericin B